Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

WAYFINDER: A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome

NCT06112275 is registered in ClinicalTrials.gov with Encoded Therapeutics as lead sponsor.

NCT NCT06112275
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06112275 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
WAYFINDER: A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome
Lead sponsor
Encoded Therapeutics
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
February 28, 2024
Completion date
September 30, 2030
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dravet syndrome